Last reviewed · How we verify
PCV15 - Part B
PCV15 is a pneumococcal conjugate vaccine that stimulates immune responses against 15 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.
PCV15 is a pneumococcal conjugate vaccine that stimulates immune responses against 15 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in adults aged 18 years and older, Prevention of pneumococcal pneumonia in adults.
At a glance
| Generic name | PCV15 - Part B |
|---|---|
| Also known as | VAXNEUVANCE™ |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains capsular polysaccharides from 15 serotypes of pneumococcus conjugated to a diphtheria toxoid protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive pneumococcal disease and pneumococcal pneumonia caused by these serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in adults aged 18 years and older
- Prevention of pneumococcal pneumonia in adults
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV15 - Part B CI brief — competitive landscape report
- PCV15 - Part B updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI